Overview

Low-dose IL-2 Treatment on Behcet's Disease

Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The study aims to explore the clinical and immunological efficacy of low-dose IL-2 on Behcet's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Interleukin-2